Daily Market Movers (30 Mar 2015)
EvaluatePharma’s EventAnalyzer delivers a daily global roundup of key events driving company valuations.
Detailing the previous day’s top 15 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.
Top 15 Gains (%) - ranked on change in share price
| Performance: Mon 30 Mar vs. Fri 27 Mar | ||||||
| Rank | Company | Listed Currency | Share Price Change | Market Cap (US$m) | Market Cap Change | Notes on Change |
| 1 | Auspex Pharmaceuticals | USD | +42% | 3193 | +937 | 30 Mar: Teva to acquire Auspex for around $3.5bn or $101 per share, a premium of 42.4% over Auspex's closing price on 27 Mar. |
| 2 | Cocrystal Pharma | USD | +24% | 842 | +160 | |
| 3 | MediGene | EUR | +20% | 201 | +33 | 30 Mar: Shares rise on 4.5x average daily trading volume. |
| 4 | Horizon Pharma | USD | +18% | 3225 | +497 | 30 Mar: Horizon to buy Hyperion Therapeutics for $1.1bn or $46 per share, a 7.6% premium over Hyperion's closing price on 27 Mar. |
| 5 | Atara Biotherapeutics | USD | +17% | 1045 | +153 | |
| 6 | GENFIT | EUR | +16% | 912 | +125 | 30 Mar: Shares rebound after plunging 44% on 26 Mar, on the failure of GFT505 in a phase II NASH trial. |
| 7 | KunWha Pharmaceutical Company | KRW | +15% | 249 | +32 | |
| 8 | Concert Pharmaceuticals | USD | +14% | 331 | +41 | 30 Mar: Company due 1.44% of the purchase price of Auspex Pharmaceuticals as a result of a license agreement. |
| 9 | Pioneer Pharma | HKD | +14% | 871 | +106 | |
| 10 | Marksans Pharma | INR | +11% | 379 | +39 | |
| 11 | Puma Biotechnology | USD | +11% | 7653 | +758 | |
| 12 | Retrophin | USD | +10% | 795 | +76 | 30 Mar: Nomura initiates coverage with a "buy" rating and price target of $31. |
| 13 | Cempra Holdings | USD | +9% | 1521 | +128 | |
| 14 | Oxford BioMedica | GBP | +9% | 466 | +38 | |
| 15 | Receptos | USD | +9% | 5049 | +398 | 30 Mar: Shares rise on 2.5x average daily trading volume. |
Excludes companies with a market cap. movement of less than US$25m.
Top 15 Losses (%) - ranked on change in share price
| Performance: Mon 30 Mar vs. Fri 27 Mar | ||||||
| Rank | Company | Listed Currency | Share Price Change | Market Cap (US$m) | Market Cap Change | Notes on Change |
| 1 | Can-Fite BioPharma | ILS | -56% | 26 | -33 | 30 Mar: Company's psoriasis treatment, CF101, fails to meet primary endpoint in a phase II/III trial. |
| 2 | BioDelivery Sciences International | USD | -24% | 550 | -177 | 30 Mar: Company's Clonidine Topical Gel fails in a phase III trial in diabetic neuropathy. |
| 3 | Cellular Biomedicine Group | USD | -8% | 368 | -31 | 30 Mar: Shares fall on 3x average daily trading volume. |
| 4 | Sorrento Therapeutics | USD | -8% | 411 | -34 | |
| 5 | Medipost | KRW | -7% | 495 | -37 | |
| 6 | TWi Pharmaceuticals | TWD | -7% | 761 | -58 | |
| 7 | OBI Pharma | TWD | -7% | 1525 | -111 | |
| 8 | Medigen Biotechnology | TWD | -7% | 633 | -46 | |
| 9 | Taiwan Liposome Company | TWD | -6% | 355 | -27 | |
| 10 | Lotus Pharmaceutical (Taiwan) | TWD | -6% | 680 | -45 | |
| 11 | Zhejiang Wolwo Bio-Pharmaceutical | CNY | -6% | 1193 | -75 | |
| 12 | Center Laboratories | TWD | -4% | 566 | -25 | |
| 13 | Fuan Pharmaceutical | CNY | -3% | 987 | -35 | |
| 14 | PharmaEngine | TWD | -3% | 843 | -29 | |
| 15 | Walvax Biotechnology | CNY | -3% | 1853 | -55 | |
Excludes companies with a market cap. movement of less than US$25m.
Disclaimer:
The above analysis is based on daily share prices supplied to Evaluate Ltd. by a third party. Evaluate Ltd. accepts no responsibility or liability for the accuracy of the data presented here. Neither should any data presented here be construed as a solicitation or offer to buy or sell any securities or related financial instruments.
Share This Article
